Results 91 to 100 of about 114,812 (257)

Oral vancomycin solution is superior to capsule in inducing clinical biomarker and endoscopic remission in children with atypical ulcerative colitis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Atypical colitis (presenting reverse gradient colitis, backwash ileitis or rectal sparing) is associated with primary sclerosing cholangitis–ulcerative colitis (PSC). Oral vancomycin has been used to manage paediatric atypical colitis with/without confirmed PSC. Different preparations had shown different efficacy.
Laura Räisänen   +4 more
wiley   +1 more source

A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PF‐07261271 in healthy participants

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim There is an unmet need for more effective therapies in inflammatory bowel disease (IBD). A single drug that blocks multiple distinct pathogenic pathways may offer therapeutic benefit superior to current monotherapies. PF‐07261271, a bispecific antibody targeting both the p40 subunit of interleukin‐12/23 and tumour necrosis factor‐like cytokine 1A ...
Srividya Neelakantan   +11 more
wiley   +1 more source

HLA TYPING OF ULCERATIVE COLITIS IN IRAN

open access: yesActa Medica Iranica, 1996
Ulcerative colitis is an acute or chronic inflammatory bowel disease that diffusely involves the colonic mucosa. the etiology of ulcerative colitis is unknown.
Froutan   +4 more
doaj  

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley   +3 more
wiley   +1 more source

Ulcerative Colitis [PDF]

open access: yesClinics in Colon and Rectal Surgery, 2004
openaire   +2 more sources

Eudragit®‐engineered pH‐responsive probiotic microspheres with enhanced gastrointestinal resistance and prolonged storage stability for inflammatory bowel disease therapy

open access: yesBMEMat, EarlyView.
This study reports the development of AMS@Eud core‐shell microspheres, combining calcium alginate and pH‐responsive Eudragit® L100, which exhibit exceptional gastrointestinal resistance and long‐term storage stability (only 5.28%–9.09% viability loss over 35 days at 4–25°C), and effectively alleviate inflammatory bowel disease via gut microbiota ...
Ming Teng   +5 more
wiley   +1 more source

Controllable engineered probiotic microspheres for treating ulcerative colitis: A cascade enzyme‐catalyzed strategy to restore intestinal redox homeostasis

open access: yesBMEMat, EarlyView.
A dual strategy integrating genetic engineering and physical encapsulation was proposed to enhance the cell viability and antioxidant properties of probiotics. The cascade antioxidant enzymes released from probiotic microspheres restore intestinal redox homeostasis by eliminating intestinal reactive oxygen species for ulcerative colitis treatment ...
Xiaolong Mao   +9 more
wiley   +1 more source

Isoform Specificity of a Compound Targeting Actin Filaments Containing Tropomyosin Tpm1.8/1.9

open access: yesCytoskeleton, EarlyView.
ABSTRACT The unbranched actin filaments in mammalian cells are usually composed of co‐polymers of a specific tropomyosin isoform with actin. Genetic manipulation has revealed that the tropomyosins largely define the functional properties of actin filaments in an isoform‐specific, non‐redundant manner.
Jeff Hook   +2 more
wiley   +1 more source

Exploring the health benefits of gut microbiota metabolites on combating ulcerative colitis via network pharmacology, bioinformatics and molecular docking

open access: yesScientific Reports
Ulcerative colitis (UC) is a leading health challenge worldwide. The evidence of the benefits of gut microbiota metabolites for the treatment of ulcerative colitis is accumulating, but the underlying mechanism remains to be further elucidated. Hence, the
Weiguo Yao   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy